Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

MannKind Plans to Cut 41% of Workforce on Drug Delays

MannKind Corp., the unprofitable biotechnology company that failed to win U.S. approval last month to market its first product, said it will cut about 41 percent of its workforce.

The firings will be completed by mid-April and reduce the number of company employees to 257, Valencia, California-based MannKind said today in a regulatory filing.

MannKind, founded by billionaire inventor Alfred Mann, is restructuring its operations to focus on winning Food and Drug Administration approval for Afrezza, an inhaled insulin for diabetes, Mann said today in a statement. The FDA on Jan. 19 asked the company for two new studies of the device in patients with Type 1 and Type 2 diabetes.

“The year ahead will be focused on the activities that are necessary to secure the approval of Afrezza,” said Mann, the company’s chairman and chief executive officer.

MannKind fell as much as 5.9 percent to $4.76 in extended trading after declining 8 cents, or 1.6 percent, to $5.06 at 4 p.m. New York time in Nasdaq Stock Market composite trading before the announcement.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.